Cargando…
Antibody Targeting of Cathepsin S Inhibits Angiogenesis and Synergistically Enhances Anti-VEGF
BACKGROUND: Angiogenesis is a key hallmark of tumourigenesis and its inhibition is a proven strategy for the development of novel anti-cancer therapeutics. An important aspect of early angiogenesis is the co-ordinated migration and invasion of endothelial cells through the hypoxic tumour tissue. Cat...
Autores principales: | Ward, Claire, Kuehn, Diana, Burden, Roberta E., Gormley, Julie A., Jaquin, Thomas J., Gazdoiu, Mihaela, Small, Donna, Bicknell, Roy, Johnston, James A., Scott, Christopher J., Olwill, Shane A. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2932732/ https://www.ncbi.nlm.nih.gov/pubmed/20824056 http://dx.doi.org/10.1371/journal.pone.0012543 |
Ejemplares similares
-
Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity
por: Kwok, Hang Fai, et al.
Publicado: (2011) -
The role of Cathepsin S as a marker of prognosis and predictor of chemotherapy benefit in adjuvant CRC: a pilot study
por: Gormley, J A, et al.
Publicado: (2011) -
A Novel High-Throughput Technique for Identifying Monoclonal Antibodies Capable of Death Receptor Induced Apoptosis
por: Kwok, Hang Fai, et al.
Publicado: (2009) -
CCL2 is transcriptionally controlled by the lysosomal protease cathepsin S in a CD74-dependent manner
por: Wilkinson, Richard D.A., et al.
Publicado: (2015) -
EDIL3 and VEGF Synergistically Affect Angiogenesis in Endothelial Cells
por: Niu, Xuping, et al.
Publicado: (2023)